Economic benefit of expanding mammography screening for breast cancer in Colombia: A cost modelling analysis

Read full text Summarise with VIRAT
Authors: Ana María Osorio, Daniel Samacá-Samacá, Melissa Diaz-Puentes, Ana María Ramos, Laura Prieto‐Pinto, María Alejandra Bravo, Sergio Cervera, José Joaquín Caicedo, Sebastián Quintero, Jorge Ceballos, Natalia Sánchez, Juliana Saavedra
+3 more Andrés F. Cardona, William Mantilla, Sandra Franco
Cited by: 0
References: 20

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Objectives: Breast cancer (BC) remains a leading cause of mortality, especially when diagnosed at advanced or metastatic stages. Early detection improves survival and reduces treatment costs. This study estimates the economic implications of expanding mammography screening coverage on breast cancer care in Colombia by modelling stage redistribution and associated direct medical treatment costs. Study design: This is a cost-benefit study to evaluate the impact of breast cancer screening strategies on the cost of care in Colombia. Methods: A 5-year Markov model estimated costs by cancer phenotype and clinical stage, utilising healthcare resource utilization data from a comprehensive Colombian cancer center. We compared current costs (31% mammography coverage) with projected costs, assuming a 70% screening rate (using the Netherlands' distribution as a reference). Results: Data from 284 Colombian BC patients were included: Luminal (59%), HER2+ (26%), and Triple-Negative BC (15%). First-year costs varied widely, ranging from early-stage Luminal (USD 10,309) to metastatic HER2+ (USD 60,612). Advanced BC significantly drove healthcare costs. By increasing screening coverage to 70%, the number of early-stage cases detected each year would increase by 56% compared to the current 33%. Increasing screening could shift diagnoses earlier, reducing the average 5-year cost per patient from $68,183 to $58,542. This would translate to a USD 164 million saving for Colombia. Conclusions: Increasing screening coverage improves patient outcomes by detecting more early-stage cases and significantly reduces healthcare expenditures by decreasing costly advanced-stage diagnoses, yielding substantial savings for the Colombian health system.

Fields of Study & Subjects

Global Cancer Incidence and Screening Health Systems Economic Evaluations Quality of Life Economic and Financial Impacts of Cancer

Publication details

Journal / source
Public Health in Practice
Volume
11
Pages
100771–100771
Publication date
28 March 2026
Language
EN